Amarin reported $58.77M in Operating Expenses for its fiscal quarter ending in March of 2025.


Operating Expenses Change Date
AbbVie USD 9.71B 96M Jun/2025
Alnylam Pharmaceuticals USD 789.89M 213.78M Jun/2025
Amarin USD 58.77M 56.06M Mar/2025
AstraZeneca USD 10.95B 1.04B Jun/2025
DBV Technologies USD 41.11M 13.74M Jun/2025
GlaxoSmithKline GBP 5.96B 663M Jun/2025
Halozyme Therapeutics USD 123.28M 48K Jun/2025
Ionis Pharmaceuticals USD 312.21M 34.21M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
Novartis USD 9.97B 1.02B Jun/2025